Compare Crispr Therapeutics AG (CRSP) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Newmont Corporation — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Newmont Corporation trades at $94.1 (market cap $101.15B). The key difference: Newmont Corporation is far larger — about 20.4× Crispr Therapeutics AG's market cap, and Newmont Corporation pays a 1.1% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NEM | |
|---|---|---|
Market Cap | $4.97B | $101.15B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $131.95 |
52-Week Low | $44.34 | $57.35 |
Enterprise Value | $3.32B | $97.90B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Newmont (NEM) trades at $93.10, down 2.3% over the past day amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.08, net income margin of 33.87%, and three consecutive quarterly earnings beats. Recent news highlights Wall Street's positive valuation view despite near-term cost pressures. Cash flow trends are robust, with operating cash flow rising to $10.33 billion in 2025.
Outlook remains favorable given analyst consensus of a $140.11 price target and 75% buy ratings. Key risks include higher unit costs impacting 2026 margins and gold price volatility. The stock offers value with solid profitability and growth, though investors should monitor cost management and gold market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
